Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaThe intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the gamesCD30: from basic research to cancer therapyThe role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosisThe use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo.Herpes simplex virus type 1-specific cytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infectionIslet lymphocyte subsets in male and female NOD mice are qualitatively similar but quantitatively distinct.Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.The immune system and gene expression microarrays--new answers to old questions.The role of TNF receptor and TNF superfamily molecules in organ transplantation.T-cell activation and transplantation tolerance.Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by BimMice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestationsNeonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells.SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential.Deciphering CD30 ligand biology and its role in humoral immunity.TNF superfamily: costimulation and clinical applicationsImmunologic basis of graft rejection and tolerance following transplantation of liver or other solid organsThe tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.Role of CD30 targeting in malignant lymphoma.Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance.The new therapeutical scenario of Hodgkin lymphoma.Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection.Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.Regulation of CD30 antigen expression and its potential significance for human disease.Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia.Abnormal anterior chamber associated immune deviation (ACAID) in 129-strain mice.Withaferin A Associated Differential Regulation of Inflammatory Cytokines.Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.Neonatal pattern of V(H) gene utilization in nonobese diabetic mice does not correlate with development of insulitis.Haplotype analysis of tumour necrosis factor receptor genes in 1p36: no evidence for association with systemic lupus erythematosusExpression of CD30 in testis and Epididymis of adult mice
P2860
Q24633761-893FE0E0-D648-499D-A748-6EEA63417086Q24683018-5A083448-DFED-4078-9C12-96EFBD809004Q26859079-B5B62B44-AAB7-447E-A2FA-9EDBAB5BD658Q26996707-FCAEDC91-7EA2-4A01-ABC6-EF492C36CDE7Q33778844-3B9312E8-0065-458C-AD9A-A8A15A08CD3BQ33799184-CC9B7B90-3CD7-4FA8-B37E-DA922AC80DF5Q33869101-79EF9D67-60F4-419C-A542-7885CBB78664Q34231085-12527844-493E-4986-BC79-70F1D8643F9FQ34378402-BD7A9E10-7A82-4789-A317-B0E14975A888Q34719084-35DF386D-A721-4E2A-9BB9-E00CD63EEBE3Q35803977-C1F7FF95-3F53-4F89-9461-5219DD281090Q36211163-17E88FE2-E760-49F5-88FB-B3BF2DA00976Q36251308-F127C6C2-17D1-4202-9672-E89402A24589Q36368539-CB684FF1-CA9B-4309-AECF-A112E07189D8Q36371167-5EAB43E3-BAA6-49ED-896C-95788DCBB005Q36375661-094311DB-71E8-4DDC-9322-17D293DE69A4Q36375728-D9DFBD6D-DA60-48F8-8758-1FDB1883ABEFQ36403649-6457548B-0B81-49B1-8D5F-E072C95AD5D9Q36505738-8ED521FC-27FD-482D-99CB-3A8463CDD8E7Q37266849-EBC265A1-B58E-47B7-8334-71A3D4EE27F7Q37400370-A55F4EC4-6848-4DCD-97F5-AA6E81AA0E1BQ37852758-3723A794-A8BD-4792-B7D6-13B92AA17733Q38191191-5FDCC940-331D-422D-9016-AEB7EFEC6B5FQ38217596-34DE78A2-DFBC-427F-AC88-E2FBA144FE27Q38513816-B5420963-B28F-41EB-B2B3-0DBA3E8198ADQ39200028-B883369F-9424-4F35-80B4-6C44033CDB5AQ40870263-3971FDDF-5787-4BCD-B1CB-932287E5C30EQ42087613-CB868A95-2DAF-41EC-8192-A4BBFA36DC30Q42441496-95DBF770-E77F-45A3-8AB3-1AE03E061044Q42508366-00503A74-EBA6-4A31-9CA5-605114115D9EQ42775424-6AFF531E-92B8-428B-8F3B-7B6136AC8DF2Q43658856-FADF5E49-989A-4063-BF0C-BA0CC2985870Q46968516-E3592814-3169-44D3-A50C-B6D87226856CQ50315781-6A250D88-050D-48AC-8914-4A938EABA715Q52563077-6EABD5C4-467B-4F69-9BCC-7F3093823764Q52935713-F48EE0D8-55F7-4904-888E-992E02FF4B38Q57606773-9D05CDBD-542F-4F75-9411-C31BD5E67D74Q58133896-379890E7-02F7-48E3-88D7-7F5D8D7006CC
P2860
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@ast
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en-gb
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@nl
type
label
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@ast
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en-gb
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@nl
prefLabel
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@ast
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en-gb
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@nl
P2093
P2860
P356
P1433
P1476
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
@en
P2093
P2860
P2888
P304
P356
10.1038/18692
P407
P577
1999-03-01T00:00:00Z
P6179
1033278912